Back to Results

Embecta Corp (EMBC)

Embecta Corp. is a healthcare company focused on medical devices for people living with diabetes in the United States and in international markets. Its product lineup includes pen needles, syringes, and safety injection devices, along with digital applications designed to support diabetes management. The company sells primarily through wholesalers and distributors. Embecta was formerly known as Berra Newco, Inc. and was founded in 1924. It is headquartered in Parsippany, New Jersey, and its common stock trades on the NASDAQ exchange under the symbol EMBC.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-EMBC
$6.77
27.9% Upside
Undervalued
$4
-24.4% Downside
Overvalued
Great
0.8%
December 1, 2026
3.4x
0.3x
299.7 M
1.587 B
83.4%
96.7%
1.4
31.1%
188.1%
Valuation • Fair Value

Embecta Corp (NASDAQ-EMBC) Fair Value by Valuation Model

Review the available estimates for Embecta Corp (NASDAQ-EMBC), including Ben Graham Formula Value, DDM Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$6.77

Estimated upside of 27.9% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

Ben Graham Formula Value

$17.14

Classic Ben Graham valuation formula reference.

DDM Fair Value

$8.19

Dividend discount model valuation reference.

Comps Fair Value

$6.29

Comparable-company valuation reference.

Analyst Price Target

$4

Analysts imply downside of 24.4%.

How to read these valuation models

Use the 6 available valuation references for Embecta Corp (NASDAQ-EMBC) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Embecta Corp (NASDAQ-EMBC)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

1.019 B

Current operating scale indicator.

Revenue Forecast

1.025 B

Forward revenue estimate.

EBITDA

281.5 M

Current operating profitability reference.

EBITDA Forecast

312.3 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Embecta Corp (NASDAQ-EMBC) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Embecta Corp (NASDAQ-EMBC)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

-2.70

No elevated caution signal from this screen.

Altman Z-Score

1.4

Lower score that deserves closer risk review.

FCF / Net Income

188.1%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Embecta Corp (NASDAQ-EMBC). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Embecta Corp (NASDAQ-EMBC)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

December 1, 2026

Days to Earnings

74

Dividend Yield

0.8%

Current income yield reference.

Payout Ratio

31.1%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Embecta Corp (NASDAQ-EMBC), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Embecta Corp (NASDAQ-EMBC) Stock Forecast & Technical Outlook

Review Embecta Corp (NASDAQ-EMBC) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Embecta Corp (NASDAQ-EMBC) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Embecta Corp (NASDAQ-EMBC) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Buy

The daily technical read for Embecta Corp (NASDAQ-EMBC) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Buy

The weekly technical read for Embecta Corp (NASDAQ-EMBC) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Embecta Corp (NASDAQ-EMBC) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Embecta Corp (NASDAQ-EMBC)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Embecta Corp (NASDAQ-EMBC) has a Hold consensus, with 0 buy, 3 hold and 0 sell recommendations in the current data set.

Buy 0
Hold 3
Sell 0
FAQ • Fast Investor Answers

Embecta Corp (NASDAQ-EMBC) Stock FAQ

Data-supported answers about Embecta Corp (NASDAQ-EMBC), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$6.77
Estimated upside 27.9%
Valuation Rating
Undervalued
Estimated upside of 27.9%
Analyst Target
$4
Implied downside 24.4%
Financial Health
Great
Current financial-health read

The current fair value estimate for Embecta Corp (NASDAQ-EMBC) is $6.77. This implies an estimated upside of 27.9% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 27.9% versus the current market price.

The available analyst price target for Embecta Corp (NASDAQ-EMBC) is $4. The analyst target implies estimated downside of 24.4%.

The current financial health read for Embecta Corp (NASDAQ-EMBC) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Embecta Corp (NASDAQ-EMBC) is December 1, 2026.

Based on the current data, dividend yield is 0.8%.

The current P/E ratio listed for Embecta Corp (NASDAQ-EMBC) is 3.4x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Embecta Corp is 299.7 M.

The current enterprise value listed for Embecta Corp is 1.587 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Embecta Corp is NASDAQ-EMBC, and the stock is listed on NASDAQ.

Embecta Corp (NASDAQ-EMBC) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Embecta Corp is 83.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Embecta Corp is 96.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABT NYSE Abbott Laboratories Fair Value Fair Market Cap 177.6 B
ISRG NASDAQ Intuitive Surgical Inc Fair Value Fair Market Cap 139 B
MDT NYSE Medtronic PLC Fair Value Fair Market Cap 117.8 B
SYK NYSE Stryker Corporation Fair Value Fair Market Cap 105.5 B
BSX NYSE Boston Scientific Corp Fair Value Undervalued Market Cap 62.81 B
EW NYSE Edwards Lifesciences Corp Fair Value Fair Market Cap 50.873 B
BDX NYSE Becton Dickinson and Co Fair Value Undervalued Market Cap 49.286 B
MDLN NASDAQ Medline Inc Fair Value Fair Market Cap 41.807 B
IDXX NASDAQ IDEXX Laboratories Inc Fair Value Fair Market Cap 40.289 B
DXCM NASDAQ DexCom Inc Fair Value Fair Market Cap 33.717 B
RMD NYSE ResMed Inc Fair Value Undervalued Market Cap 32.188 B
ALC NYSE Alcon AG Fair Value Undervalued Market Cap 31.559 B
GEHC NASDAQ GE HealthCare Technologies Inc Fair Value Undervalued Market Cap 28.967 B
PHG NYSE Koninklijke Philips NV ADR Fair Value Undervalued Market Cap 24.25 B
STE NYSE STERIS plc Fair Value Undervalued Market Cap 19.991 B
ZBH NYSE Zimmer Biomet Holdings Inc Fair Value Undervalued Market Cap 18.189 B
SOLV NYSE Solventum Corp Fair Value Fair Market Cap 15.123 B
PEN NYSE Penumbra Inc Fair Value Fair Market Cap 12.51 B
BAX NYSE Baxter International Inc Fair Value Undervalued Market Cap 11.788 B
SNN NYSE Smith & Nephew SNATS Inc Fair Value Undervalued Market Cap 11.577 B